Financials data is unavailable for this security.
View more
Year on year Avalo Therapeutics Inc had revenues fall -89.34% from 18.05m to 1.92m, though the company grew net income from a loss of 41.66m to a smaller loss of 31.54m.
| Gross margin | 182.20% |
|---|---|
| Net profit margin | -970.49% |
| Operating margin | -7,665.73% |
| Return on assets | -12.46% |
|---|---|
| Return on equity | -45.48% |
| Return on investment | -26.07% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Avalo Therapeutics Inc fell by 5.77m. Cash Flow from Financing totalled 25.04m or 1,301.56% of revenues. In addition the company used 30.68m for operations while cash used for investing totalled 133.00k.
| Cash flow per share | -1.88 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 2.35 |
|---|---|
| Tangible book value per share | 1.26 |
More ▼
Balance sheet in USDView more
| Current ratio | 1.42 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
